# Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

> **NCT01359956** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute, Naples** · enrollment: 269 (actual)

## Conditions studied

- Malignant Melanoma
- Recurrent Melanoma

## Interventions

- **DRUG:** Dacarbazine
- **DRUG:** Fotemustine
- **DRUG:** Interferon Alfa-2b

## Key facts

- **NCT ID:** NCT01359956
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359956, "Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01359956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*